vadimezan has been researched along with Lung Neoplasms in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 8 (42.11) | 29.6817 |
| 2010's | 9 (47.37) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Bryan Bell, R; Chen, G; Chen, Z; Ci, T; Dotti, G; Gu, Z; Li, H; Li, R; Meng, H; Wang, J; Wang, Z; Wen, D | 1 |
| Albelda, SM; Cheng, G; Fridlender, ZG; Jassar, A; Kapoor, V; Levy, L; Mishalian, I; Singhal, S; Sun, J; Wang, LC | 1 |
| Aghaei, M; Downey, CM; Jirik, FR; Schwendener, RA | 1 |
| He, ZX; Pan, ST; Qiu, JX; Wang, D; Yang, T; Yang, YX; Zhang, X; Zhou, SF; Zhou, ZW | 1 |
| Cao, N; Du, G; Duan, Y; Guo, Z; Han, G; Li, G; Li, H; Lin, H; Liu, L; Ma, X | 1 |
| Döme, B; Magyar, M | 1 |
| Chouaid, C; Freitag, L; Gibbs, D; Jameson, MB; Lafitte, JJ; Mainwaring, PN; McKeage, MJ; Quoix, E; Reck, M; Rosenthal, MA; Serke, M; Sullivan, R; Von Pawel, J | 1 |
| Freitag, L; Gibbs, D; Jameson, MB; Mainwaring, PN; McKeage, MJ; Reck, M; Rosenthal, MA; Sullivan, R; Von Pawel, J | 1 |
| Castaldo, V; Colantuoni, G; Gridelli, C; Maione, P; Rossi, A; Rossi, E; Sacco, PC | 1 |
| Hida, T; Hirashima, T; Horai, T; Horio, Y; Kobayashi, K; Nishio, M; Shi, MM; Tamiya, M; Tanii, H; Yamamoto, N | 1 |
| McKeage, MJ | 1 |
| Boerner, SA; Hunsberger, S; Lorusso, PM | 1 |
| Albert, I; Douillard, JY; Fan, X; Fandi, A; Heo, DS; Lara, PN; Losonczy, G; McKeage, MJ; Nakagawa, K; Reck, M; Scagliotti, G; von Pawel, J | 1 |
| Cathomas, R; Erdmann, A; Früh, M; Fustier, P; Krasniqi, F; Küttel, E; Mamot, C; Pless, M; Rauch, D; Siano, M; Simcock, M; Tscherry, G; Zippelius, A | 1 |
| Raben, D; Ryan, A | 1 |
| Albelda, SM; Burdick, MD; Cheung, L; Ching, LM; Jassar, AS; Kaiser, LR; Kapoor, V; Silverberg, MB; Strieter, RM; Sun, J; Suzuki, E | 1 |
| Ching, LM; Roberts, ZJ; Vogel, SN | 1 |
| Bibby, MC; Double, JA; Laws, AL; Matthew, AM | 1 |
4 review(s) available for vadimezan and Lung Neoplasms
| Article | Year |
|---|---|
[Tumor vasculature as a therapeutic target in non-small cell lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Imidazoles; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Xanthones | 2008 |
Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Diketopiperazines; Endothelial Cells; Humans; Imidazoles; Lung Neoplasms; Pericytes; Piperazines; Stilbenes; Sulfonamides; Xanthones | 2009 |
Clinical trials of vascular disrupting agents in advanced non--small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Lung Neoplasms; Xanthones | 2011 |
Vascular-targeting agents and radiation therapy in lung cancer: where do we stand in 2005?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Humans; Lung Neoplasms; Neovascularization, Pathologic; Organophosphorus Compounds; Vascular Endothelial Growth Factors; Xanthones | 2005 |
5 trial(s) available for vadimezan and Lung Neoplasms
| Article | Year |
|---|---|
Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome; Xanthones | 2008 |
Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Xanthones | 2009 |
Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Remission Induction; Survival Rate; Tissue Distribution; Treatment Outcome; Xanthones | 2011 |
Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Paclitaxel; Quality of Life; Surveys and Questionnaires; Treatment Failure; Xanthones | 2011 |
Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Small Cell Lung Carcinoma; Treatment Outcome; Xanthones | 2013 |
10 other study(ies) available for vadimezan and Lung Neoplasms
| Article | Year |
|---|---|
Disrupting tumour vasculature and recruitment of aPDL1-loaded platelets control tumour metastasis.
Topics: Animals; Antineoplastic Agents; B7-H1 Antigen; Blood Platelets; Cell Line, Tumor; Female; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasm Metastasis; Neoplasms; Platelet Activation; Platelet Transfusion; Xanthones | 2021 |
Using macrophage activation to augment immunotherapy of established tumours.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Female; Immunotherapy; Lung Neoplasms; Macrophage Activation; Macrophages; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Myeloid Cells; Neutrophils; Tumor Microenvironment; Xanthones | 2013 |
DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization.
Topics: Adenocarcinoma; Animals; Carcinoma, Non-Small-Cell Lung; Cell Membrane Permeability; Cell Polarity; Clodronic Acid; Humans; Inflammation; Liposomes; Lung Neoplasms; Macrophages; Male; Membrane Proteins; Mice, Transgenic; Necrosis; Neovascularization, Pathologic; Nucleotides, Cyclic; Phenotype; ras Proteins; Subcutaneous Tissue; Tumor Suppressor Protein p53; Xanthones; Xenograft Model Antitumor Assays | 2014 |
Proteomic response to 5,6-dimethylxanthenone 4-acetic acid (DMXAA, vadimezan) in human non-small cell lung cancer A549 cells determined by the stable-isotope labeling by amino acids in cell culture (SILAC) approach.
Topics: Amino Acids; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Proliferation; Cell Survival; Humans; Isotope Labeling; Lung Neoplasms; Neoplasm Proteins; Proteome; Proteomics; Reactive Oxygen Species; Signal Transduction; Tumor Cells, Cultured; Xanthones | 2015 |
Tumor interstitial fluid promotes malignant phenotypes of lung cancer independently of angiogenesis.
Topics: Animals; Apoptosis; Aquaporin 1; Autophagy; Carcinoma, Lewis Lung; Cell Movement; Cell Proliferation; Disease Progression; Epithelial-Mesenchymal Transition; Extracellular Fluid; Female; Humans; Hydroxyindoleacetic Acid; Inflammation; Lung Neoplasms; Mice; Mice, Inbred C57BL; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplastic Stem Cells; Neovascularization, Pathologic; Phenotype; Platelet Endothelial Cell Adhesion Molecule-1; Wound Healing; Xanthones | 2015 |
Molecule of the month. Vadimezan.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Prostatic Neoplasms; Treatment Outcome; Xanthones | 2009 |
Clinical development of vascular disrupting agents: what lessons can we learn from ASA404?
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase III as Topic; Data Interpretation, Statistical; Drug Synergism; Female; Humans; Lung Neoplasms; Molecular Targeted Therapy; Neoplasms; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Treatment Failure; Vascular Endothelial Growth Factor A; Xanthones | 2011 |
Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Chemokines; Cytokines; Disease Models, Animal; Immunotherapy; Lung Neoplasms; Macrophages; Membrane Glycoproteins; Mesothelioma; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Neovascularization, Pathologic; Perforin; Pore Forming Cytotoxic Proteins; Xanthones | 2005 |
IFN-beta-dependent inhibition of tumor growth by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Topics: Animals; Antineoplastic Agents; Blood Vessels; Carcinoma, Lewis Lung; Chemokine CXCL10; Female; Interferon-beta; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Xanthones | 2008 |
Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Survival; Colonic Neoplasms; Hemorrhage; Humans; Lung Neoplasms; Mice; Mice, Inbred Strains; Mice, Nude; Necrosis; Species Specificity; Tumor Cells, Cultured; Xanthenes; Xanthones | 1995 |